Short answer
Biohaven Ltd. (BHVN) filed its fiscal 2025 10-K annual report with the SEC on Mar 2, 2026.
- Top risk flagged: Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
FY2025 key financial metrics · XBRL
- Net income
- −$739M
- +12.7% YoY
- EPS (diluted)
- −$6.86
- +26.1% YoY
- ROE
- -1418.8%
- −1219.0 pp YoY
- Operating cash flow
- −$609M
- −4.6% YoY
Source: XBRL data from the Biohaven Ltd. (BHVN) FY2025 10-K on SEC EDGAR. USD.
Biohaven Ltd. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
- New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
- Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
- Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
- Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks
Management Discussion & Analysis
- No management outlook, guidance, or key emerging risks mentioned
- Text focuses on industry data sources, estimates, and trademark notices
Risk Factors
- Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
- Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
- Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
- Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
- Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.